AcquisitionsApr 16, 2026, 07:26 AM
MeiraGTx acquires RPGR gene therapy assets for $25M upfront
AI Summary
MeiraGTx Holdings plc acquired a gene therapy product for X-linked retinitis pigmentosa (RPGR Product) from Janssen Pharmaceuticals, Inc. The acquisition includes an upfront cash payment of $25 million. MeiraGTx will also pay a contingent consideration of $50 million upon achieving US regulatory approval and $250 million in aggregate US net sales, along with mid-teens percentage royalties on future global net sales starting July 2029. This strategic acquisition enhances MeiraGTx's pipeline in ocular gene therapy.
Key Highlights
- Acquired RPGR gene therapy assets from Janssen Pharmaceuticals.
- Upfront cash payment of $25,000,000.
- Contingent payment of $50,000,000 upon US regulatory approval and $250M US net sales.
- Mid-teens percentage royalties on global net sales from July 1, 2029.